Lanreotide depot/autogel antitumor activity in intestinal/pancreatic neuroendocrine tumors (NETs) was demonstrated in the phase-3 CLARINET study (NCT00353496), based on significantly prolonged progressionfree survival (PFS) versus placebo. | Tumor growth rate as a metric of progression response and prognosis in pancreatic and intestinal neuroendocrine tumors